| Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma: the oncogenic role of the ligands A Almazán-Moga, P Zarzosa, C Molist, P Velasco, J Pyczek, ... British journal of cancer 117 (9), 1314-1325, 2017 | 36 | 2017 |
| miRNA-7 and miRNA-324-5p regulate alpha9-Integrin expression and exert anti-oncogenic effects in rhabdomyosarcoma C Molist, N Navarro, I Giralt, P Zarzosa, G Gallo-Oller, G Pons, ... Cancer Letters 477, 49-59, 2020 | 25 | 2020 |
| Patient-derived xenografts for childhood solid tumors: a valuable tool to test new drugs and personalize treatments P Zarzosa, N Navarro, I Giralt, C Molist, A Almazán-Moga, I Vidal, ... Clinical and Translational Oncology 19, 44-50, 2017 | 19 | 2017 |
| Dickkopf proteins and their role in cancer: A family of Wnt antagonists with a dual role I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ... Pharmaceuticals 14 (8), 810, 2021 | 15 | 2021 |
| Hedgehog pathway inhibition hampers sphere and holoclone formation in rhabdomyosarcoma A Almazán-Moga, P Zarzosa, I Vidal, C Molist, I Giralt, N Navarro, ... Stem Cells International 2017, 2017 | 14 | 2017 |
| Dickkopf-1 inhibition reactivates Wnt/β-catenin signaling in rhabdomyosarcoma, induces myogenic markers in vitro and impairs tumor cell survival in vivo I Giralt, G Gallo-Oller, N Navarro, P Zarzosa, G Pons, A Magdaleno, ... International Journal of Molecular Sciences 22 (23), 12921, 2021 | 5 | 2021 |
| Targeting the hedgehog pathway in rhabdomyosarcoma P Zarzosa, L Garcia-Gilabert, R Hladun, G Guillén, G Gallo-Oller, G Pons, ... Cancers 15 (3), 727, 2023 | 4 | 2023 |
| Integrin alpha9 emerges as a key therapeutic target to reduce metastasis in rhabdomyosarcoma and neuroblastoma N Navarro, C Molist, J Sansa-Girona, P Zarzosa, G Gallo-Oller, G Pons, ... Cellular and Molecular Life Sciences 79 (11), 546, 2022 | 3 | 2022 |
| Analysis of cancer genomic amplifications identifies druggable collateral dependencies within the amplicon G Pons, G Gallo-Oller, N Navarro, P Zarzosa, J Sansa-Girona, ... Cancers 15 (6), 1636, 2023 | 1 | 2023 |
| Abstract A27: Ligand-dependent Hedgehog pathway activation in rhabdomyosarcoma J Roma, A Almazán-Moga, P Zarzosa, P Velasco, C Molist, I Giralt, I Vidal, ... Clinical Cancer Research 24 (2_Supplement), A27-A27, 2018 | 1 | 2018 |
| TRIB3 silencing promotes the downregulation of Akt pathway and PAX3-FOXO1 in high-risk rhabdomyosarcoma G Gallo-Oller, G Pons, J Sansa-Girona, N Navarro, P Zarzosa, ... Experimental Hematology & Oncology 13 (1), 38, 2024 | | 2024 |
| Combined inhibition of MDM2 and PARP lead to a synergistic anti-tumoral response in p53 wild-type rhabdomyosarcoma G Pons, G Gallo-Oller, L García-Gilabert, P Zarzosa, J Sansa-Girona, ... Cancer Research 84 (6_Supplement), 5473-5473, 2024 | | 2024 |
| THE ONCOGENIC ROLE OF HEDGEHOG PATHWAY CO-RECEPTORS IN RHABDOMYOSARCOMA: EXPANDING KNOWLEDGE TO DISCOVER NEW THERAPEUTIC TARGETS J Roma, P Zarzosa, S Gallego Melcon, J Sanchez De Toledo, L Moreno, ... PEDIATRIC BLOOD & CANCER 69, S258-S259, 2022 | | 2022 |
| A novel and potent strategy for blocking the Hedgehog pathway to treat rhabdomyosarcoma P Zarzosa, N Navarro, J Sansa-Girona, G Pons, G Gallo-Oller, ... European Journal of Cancer 174, S28, 2022 | | 2022 |
| Ligand-dependent Hedgehog pathway activation in rhabdomyosarcoma J Roma, A Almazan-Moga, P Zarzosa, P Velasco, C Molist, I Giralt, I Vidal, ... CLINICAL CANCER RESEARCH 24 (2), 49-50, 2018 | | 2018 |
| Ligand-dependent Hedgehog pathway activation in Rhabdomyosarcoma A Almazán-Moga, P Zarzosa, C Molist, P Velasco, J Pyczek, ... | | 2017 |
| Research Article Hedgehog Pathway Inhibition Hampers Sphere and Holoclone Formation in Rhabdomyosarcoma A Almazán-Moga, P Zarzosa, I Vidal, C Molist, I Giralt, N Navarro, ... | | 2017 |
